Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy

Annals of Neurology

Volumn 74, Issue 4, 2013, Pages 560-568

  Mazzuferi, Manuela ^a   Kumar, Gaurav ^a   Van Eyll, Jonathan ^a   Danis, Benedicte ^a   Foerch, Patrik ^a   Kaminski, Rafal M ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CALCIUM BINDING PROTEIN; COMPLEMENTARY DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; PILOCARPINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; COMPUTER PROGRAM; EPILEPSY; EPILEPTIC STATE; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEIZURE; TEMPORAL LOBE EPILEPSY;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; EPILEPSY; GENE EXPRESSION REGULATION; GLUTATHIONE TRANSFERASE; HEME OXYGENASE-1; HIPPOCAMPUS; HUMANS; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PILOCARPINE;

EID: 84890114703     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23940     Document Type: Article

References (41)

1. Benardo LS,. Prevention of epilepsy after head trauma: do we need new drugs or a new approach? Epilepsia 2003; 44 (suppl 10): 27-33.
2. Löscher W, Schmidt D,. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52: 657-678.
3. Temkin NR,. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515-524.
4. Jimenez-Mateos EM, Engel T, Merino-Serrais P, et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med 2012; 18: 1087-1094.
5. McClelland S, Flynn C, Dubé C, et al. Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann Neurol 2011; 70: 454-464.
6. Kobow K, Blümcke I,. The methylation hypothesis: do epigenetic chromatin modifications play a role in epileptogenesis? Epilepsia 2011; 52 (suppl 4): 15-19.
7. Kaspar JW, Niture SK, Jaiswal AK,. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009; 47: 1304-1309.
8. Lee JM, Johnson JA,. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 2004; 37: 139-143.
9. Nguyen T, Sherratt PJ, Pickett CB,. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003; 43: 233-260.
10. Hybertson BM, Gao B, Bose SK, et al. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011; 32: 234-246.
11. Rojo AI, Innamorato NG, Martin-Moreno AM, et al. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010; 58: 588-598.
12. Innamorato NG, Jazwa A, Rojo AI, et al. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 2010; 5: e11838.
13. Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007; 66: 75-85.
14. Kanninen K, Heikkinen R, Malm T, et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 16505-16510.
15. Winden KD, Karsten SL, Bragin A, et al. A systems level, functional genomics analysis of chronic epilepsy. PLoS One 2011; 6: e20763.
16. Kraft AD, Lee JM, Johnson DA, et al. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. J Neurochem 2006; 98: 1852-1865.
17. Malhotra D, Portales-Casamar E, Singh A, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010; 38: 5718-5734.
18. Boudreau RL, Martins I, Davidson BL,. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 2009; 17: 169-175.
19. Urabe M, Ding C, Kotin RM,. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-1943.
20. Paradiso B, Marconi P, Zucchini S, et al. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 2009; 106: 7191-7196.
21. Mazzuferi M, Kumar G, Rospo C, et al. Rapid epileptogenesis in the mouse pilocarpine model: video-EEG, pharmacokinetic and histopathological characterization. Exp Neurol 2012; 238: 156-167.
22. Racine RJ,. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
23. Schadt EE, Lamb J, Yang X, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005; 37: 710-717.
24. Scherzer CR, Offe K, Gearing M, et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004; 61: 1200-1205.
25. Thomassen M, Tan Q, Kruse TA,. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat 2009; 113: 239-249.
26. Zhang M, An C, Gao Y, et al. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 2013; 100: 30-47.
27. McCown TJ,. The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. Drug News Perspect 2010; 23: 281-286.
28. McCown TJ,. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2011; 11: 181-188.
29. Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009; 106: 2933-2938.
30. Vargas MR, Johnson DA, Sirkis DW, et al. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008; 28: 13574-13581.
31. LaPash Daniels CM, Austin EV, Rockney DE, et al. Beneficial effects of Nrf2 overexpression in a mouse model of Alexander disease. J Neurosci 2012; 32: 10507-10515.
32. Kossoff EH, Hartman AL,. Ketogenic diets: new advances for metabolism-based therapies. Curr Opin Neurol 2012; 25: 173-178.
33. Milder JB, Liang LP, Patel M,. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. Neurobiol Dis 2010; 40: 238-244.
34. Sloviter RS, Bumanglag AV, Schwarcz R, et al. Abnormal dentate gyrus network circuitry in temporal lobe epilepsy. In:, Noebels JL, Avoli M, Rogawski MA, et al, eds. Jasper's basic mechanisms of the epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information, 2012. Available at: http://www.ncbi.nlm.nih.gov/books/NBK98207/. Accessed June 2013.
35. Pitkänen A, Nissinen J, Nairismägi J, et al. Progression of neuronal damage after status epilepticus and during spontaneous seizures in a rat model of temporal lobe epilepsy. Prog Brain Res 2002; 135: 67-83.
36. do Nascimento AL, Dos Santos NF, Campos PF, et al. Neuronal degeneration and gliosis time-course in the mouse hippocampal formation after pilocarpine-induced status epilepticus. Brain Res 2012; 1470: 98-110.
37. Bernasconi N, Natsume J, Bernasconi A,. Progression in temporal lobe epilepsy: differential atrophy in mesial temporal structures. Neurology 2005; 65: 223-228.
38. Vezzani A, Granata T,. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46: 1724-1743.
39. Vezzani A, Auvin S, Ravizza T, et al. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In:, Noebels JL, Avoli M, Rogawski MA, et al, eds. Jasper's basic mechanisms of the epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information, 2012. Available at: http://www.ncbi.nlm.nih.gov/books/NBK98146/. Accessed June 2013.
40. Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 2013; 10: 30.
41. Copple IM,. The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv Pharmacol 2012; 63: 43-79.